SYNGENE INTERNATIONAL LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 694.4 INR | +0.52% |
|
+3.77% | -1.00% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 34.89B 419M | Sales 2025 * | 38.24B 459M | Capitalization | 275B 3.3B |
|---|---|---|---|---|---|
| Net income 2024 | 5.1B 61.27M | Net income 2025 * | 5.67B 68.16M | EV / Sales 2024 | 7.73 x |
| Net cash position 2024 | 9.35B 112M | Net cash position 2025 * | 9.1B 109M | EV / Sales 2025 * | 6.94 x |
| P/E ratio 2024 |
55.4
x | P/E ratio 2025 * |
50.3
x | Employees | 6,847 |
| Yield 2024 |
0.18% | Yield 2025 * |
0.21% | Free-Float | 44.65% |
More Fundamentals
* Assessed data
More news
Latest transcript on Syngene International Limited
More recommendations
More press releases
| 1 day | +0.46% | ||
| 1 week | +3.70% | ||
| Current month | +0.70% | ||
| 1 month | -1.60% | ||
| 3 months | -7.21% | ||
| 6 months | -3.96% | ||
| Current year | -1.06% |
1 week
668.10
697.60
1 month
649.25732.80
Current year
649.25774.00
1 year
649.25860.25
3 years
510.05860.25
5 years
212.55860.25
10 years
147.50860.25
| Managers | Title | Age | Since |
|---|---|---|---|
Jonathan Hunt
CEO | Chief Executive Officer | 55 | 15-02-28 |
Sibaji Biswas
DFI | Director of Finance/CFO | - | 19-12-17 |
| Chairman | 71 | 94-11-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 94-11-17 | |
| Director/Board Member | 67 | 17-07-30 | |
Jonathan Hunt
CEO | Chief Executive Officer | 55 | 15-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 4 M€ | -4.41% | - | |
| 0.00% | 112 M€ | +5.31% | - | |
| 0.00% | 34 M€ | +4.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 694.4 | +0.52% | 1 170 354 |
| 24-05-18 | 690.6 | -0.03% | 34,598 |
| 24-05-17 | 690.8 | +0.60% | 696,455 |
| 24-05-16 | 686.7 | +1.96% | 1,503,049 |
| 24-05-15 | 673.5 | +0.64% | 948,370 |
Delayed Quote NSE India S.E., May 21, 2024 at 04:15 am EDT
More quotes
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.
Calendar
2024-05-24
- Investor Meeting - GIC
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
690.6
INR
Average target price
725.1
INR
Spread / Average Target
+4.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.06% | 3.3B | |
| +41.79% | 54.04B | |
| -0.56% | 41.92B | |
| +49.67% | 41.96B | |
| -7.20% | 28.35B | |
| +12.59% | 26.35B | |
| -21.51% | 19B | |
| +6.92% | 13B | |
| +24.91% | 12.19B | |
| +29.60% | 12.28B |
- Stock Market
- Equities
- SYNGENE Stock